1. Introduction {#s0005}
===============

Approximately one third of the global population is infected with *Mycobacterium tuberculosis* (*M. tuberculosis*), the etiologic agent responsible for tuberculosis (TB). While many individuals who harbour *M. tuberculosis* never develop active disease, TB is often lethal and is estimated to have been responsible for 1.5 million deaths in the year 2013 ([@bb0310]). Multidrug-resistant (MDR) TB, which is defined as *in vitro* resistance to both rifampin and isoniazid, is a public health problem of increasing importance, with an estimated 480,000 incident cases in 2013 ([@bb0310]). Treatment of drug-resistant TB is more complex, lengthy, costly, toxic, and ultimately less successful at eradicating *M. tuberculosis* infection. With few novel antitubercular antibiotics in development, the emergence of extensively drug-resistant (XDR) *M. tuberculosis* strains (defined as MDR with additional resistance to both quinolones and second-line injectable agents) and the lack of effective treatment regimens have highlighted the potential to repurpose existing antibiotics in innovative ways ([@bb0315]).

*M. tuberculosis* has been considered innately resistant to β-lactam antibiotics, due to β--lactamase activity and the presence of non-classical transpeptidases in their cell wall ([@bb0140], [@bb0120]). *M. tuberculosis* possesses a highly active β-lactamase, BlaC, that rapidly hydrolyzes many β-lactam drugs, rendering them ineffective ([@bb0140]). Additionally, the existence of non-classical transpeptidases that crosslink the peptidoglycan cell wall of *M. tuberculosis* are thought to contribute to innate resistance to β-lactams ([@bb0120], [@bb0075]).

Despite these barriers, there may be opportunities for clinical treatment of drug-resistant *M. tuberculosis* with β-lactam antibiotics ([@bb0245], [@bb0160]). The addition of clavulanate, an oral β-lactamase inhibitor, irreversibly inhibits BlaC, and can enhance β-lactam activity against *M. tuberculosis in vitro* ([@bb0295], [@bb0135]). Furthermore, the carbapenem class of β-lactams is relatively resistant to hydrolysis by β-lactamases, and addition of clavulanate has been shown to further decrease the minimum inhibitory concentration (MIC) ([@bb0140]). Meropenem/clavulanate has been shown to have high *in vitro* activity against XDR strains, but its high cost and intravenous dosing present challenges to its widespread use ([@bb0140], [@bb0115]). The laboratory strain of *M. tuberculosis*, H37Rv, and multiple drug-susceptible clinical isolates have been shown to be resistant to β-lactams as well as β-lactams plus β-lactamase inhibitors *in vitro*, but it is not yet clear to what extent the wider *M. tuberculosis* population may be susceptible to these antibiotics. If drug-resistant strains are generally more susceptible to this antibiotic class, then one might envision an expanded role for β-lactams in the treatment of drug-resistant TB, for which currently there are limited treatment options.

Here we describe an investigation of 89 South African clinical isolates and two reference strains of *M. tuberculosis* of varying drug susceptibility patterns. We determined the range of MICs to clinically available β-lactam antibiotics and used whole-genome sequencing (WGS) to understand the genetic basis of variability with respect to amoxicillin/clavulanate susceptibility. Our results provide insight into the clinical role of β-lactams in the treatment of drug-resistant TB and potential molecular markers of amoxicillin/clavulanate susceptibility.

2. Methods {#s0010}
==========

2.1. Clinical Isolates of *M. tuberculosis* {#s0015}
-------------------------------------------

We selected a subset of 86 clinical isolates of *M. tuberculosis* from our larger sequenced strain set ([@bb0045]) for inclusion in this study. Briefly, sputum specimens were collected in KwaZulu-Natal, South Africa from 2008 to 2012 as part of a provincial drug-resistance surveillance study ([@bb0005]) and a prospective collection effort of patients newly initiating XDR regimens ([@bb0235]). Biomedical Research Ethics Council (BREC) approval from the University of KwaZulu-Natal was granted for whole genome sequencing of clinical strains. On all study isolates, drug susceptibility testing by critical concentration was performed prospectively for first and second-line TB drugs. The clinical isolate set represented diverse first and second-line drug susceptibility patterns, with 18 susceptible, three mono-drug resistant, five poly-drug resistant, 23 MDR and 37 XDR isolates.

2.2. Additional *M. tuberculosis* Strain {#s0020}
----------------------------------------

In addition to 86 clinical isolates recently isolated in South Africa, we also selected five additional strains for inclusion in this study, for a total of 91 unique isolates. These included reference strains H37Rv and CDC1551, which are both known to be fully susceptible to first and second-line TB drugs. Additionally, three clinical isolates that had previously been collected in KwaZulu-Natal ([@bb0165], [@bb0145]) were resequenced and included in this study. These were KZN4207, KZN1435 and KZN605, which have first/second-line drug susceptibility patterns of: susceptible, MDR and XDR, respectively.

2.3. β-lactam MIC Determination {#s0025}
-------------------------------

The World Health Organization (WHO) does not recommend a standard methodology for β-lactam susceptibility or resistance testing in *M. tuberculosis*, thus we utilized the Microplate Alamar Blue Assay (MABA) ([@bb0050]) to determine the MIC of each strain to β-lactams alone, or β-lactams in combination with clavulanate, a β-lactamase inhibitor, as previously described ([@bb0205]). The β-lactams and concentrations utilized were amoxicillin (0.5 μg/mL to 32 μg/mL) and meropenem (0.25 μg/mL to 16 μg/mL). Briefly, 10^4^ colony forming units (CFU) of a mid to late-log culture of each strain was plated onto a 96-well microplate in the presence of serial drug-dilutions with or without 2.5 μg/mL of clavulanate. Following seven days in culture, the lowest concentration of drug leading to at least a 90% reduction of bacterial growth signal by MABA was recorded as the MIC. Each assay was performed between one to 6 times on each isolate.

2.4. β-lactam Susceptibility Definitions {#s0030}
----------------------------------------

Based on favourable pharmacokinetics that would be necessary for clinical treatment ([@bb0305]), susceptibility to amoxicillin was defined as an MIC ≤ 4.0 μg/mL, and resistance as an MIC \> 4.0 μg/mL; susceptibility to amoxicillin/clavulanate was defined as an MIC ≤ 4.0 μg/mL/2.5 μg/mL, and resistance as an MIC \> 4.0 μg/mL/2.5 μg/mL. Susceptibility to meropenem was defined as an MIC ≤ 12.0 μg/mL, and resistance as an MIC \> 12.0 μg/mL; susceptibility to meropenem/clavulanate was defined as an MIC ≤ 12.0 μg/mL/2.5 μg/mL, and resistance as an MIC \> 12.0 μg/mL. We note that our association analysis used the amoxicillin/clavulanate MIC values directly, without dichotomization of resistant *vs.* susceptible.

2.5. β-lactamase Activity Testing {#s0035}
---------------------------------

A subset of 10 *M. tuberculosis* isolates with varying average MICs to amoxicillin/clavulanate (range 0.5 μg/mL to \> 32 μg/mL of amoxicillin in combination with 2.5 μg/mL clavulanate) underwent qualitative testing of their β-lactamase activity by nitrocefin hydrolysis. Nitrocefin (Calbiochem), a chromogenic β-lactamase substrate, was reconstituted in dimethyl sulfoxide (DMSO) to achieve 1 mg/mL. 60 μL of nitrocefin was diluted into 3 mL of phosphate buffered saline (PBS) nitrocefin to create a working solution. Mid to late log cultures of *M. tuberculosis* were diluted in PBS, and 10^5^ colony forming units of each strain were plated into a 96-well plate. 100 μL of the nitrocefin working solution was added. Cultures were monitored for a color change from yellow to red that occurs with nitrocefin hydrolysis.

2.6. Whole-genome Sequencing {#s0040}
----------------------------

Whole-genome sequencing had been performed on all included strains as previously described and published in Cohen et al. ([@bb0045]). Briefly, mycobacterial strains were single colony selected, and genomic DNA was extracted using published methods ([@bb0175]). Library preparation and whole-genome sequencing were performed on the Illumina HiSeq 2000 at the Broad Institute in Boston, MA, as previously described ([@bb0290]). Both short (180 bp) and large (3--5 Kbp) insert paired-end libraries were created from each sample and sequenced using a read length of 101 bp. All sequencing data were retrieved from the Sequence Read Archive NCBI umbrella BioProject identifier PRJNA183624.

2.7. *In silico* Spoligotyping {#s0045}
------------------------------

*In vitro* spoligotypes are derived by a hybridization assay which determines whether or not each of 43 probe sequences (each 25 bp in length) hybridizes against a sample of DNA ([@bb0150]). Here spoligotypes were determined *in silico* from Illumina sequence reads by extraction of 25 bp sequences and their reverse complements from all possible positions, and subsequent search across this set for a match for each probe sequence. In the *in vitro* assay, probes may hybridize even if the sequences do not match exactly, and thus we allowed up to two nucleotide mismatches per probe. Hybridization patterns were assigned to known *M. tuberculosis* clades/lineages by comparison of exact pattern matches in the international SITVIT database ([@bb0065]) and interrogation of the TB Insight: TB-Lineage database ([@bb0280]). Lineage designations were converted to the standardised nomenclature as presented in Gagneux et al. ([@bb0100]).

2.8. Single nucleotide variant calling {#s0050}
--------------------------------------

Illumina reads for each of 91 strains were trimmed using *seqtk* (<https://github.com/lh3/seqtk> version 1.0-r31) with a Phred quality threshold of 0.01. Trimmed reads were mapped to the H37Rv reference genome (accession [NC_000962.3](ncbi-n:NC_000962.3){#ir0010}) using BWA ([@bb0185]). Subsequent processing by SAMTools ([@bb0190]) removed duplications, merged reads from different sequencing runs of the same isolate and removed unpaired reads. SNPs and small indels (SNVs) were called using SNVer ([@bb0300]) in a monoploid mode with default parameters, with the exception that the minimum base quality threshold was increased to q20. We also enforced a minimum frequency of five reads, in each of the forward and reverse orientations, supporting each SNV call. Variants for which the maximum a-posteriori genotype estimation as computed by SNVer did not support any allele, for which depth was less than 10, strand bias was smaller than 0.05, or *p* \> 10^− 10^ were excluded from subsequent analyses.

2.9. Phylogenetic Reconstruction {#s0055}
--------------------------------

Bayesian inference of phylogeny as implemented in MrBayes ([@bb0260]) was performed based on substitution patterns of single nucleotides at conserved genomic sites (*i.e.* for which high confidence SNP calls were obtained across all isolates). Genomic regions that are known to be prone to erroneous mapping of reads, namely repeat regions, mobile elements, phage proteins, PE and PPE proteins, were excluded ([@bb0025]). *Mycobacterium canettii* CIPT 140010059 (accession: NC_015848) was used as an outgroup for phylogenetic reconstruction. A generalized time-reversible (GTR) evolutionary model with gamma distributed rate variation across sites was applied (1,000,000 Markov chain Monte Carlo runs sampled every 1000 generations after a relative burn-in of 0.25, yielding a total of 750 replicates). As association tests require a phylogeny that estimates relatedness among isolates in terms of evolutionary time ([@bb0155]), a molecular clock constraint was imposed on branch lengths, enforcing all the leaves to be equidistant from the root. For visualization purposes, a tree with branch lengths that reflected the number of substitutions was also inferred ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}).

2.10. Gene-content Analysis {#s0060}
---------------------------

*De novo* sequence assemblies were annotated by Prokka ([@bb0275]). Nucleotide sequences for all annotated coding sequence (CDS) regions were added to those annotated within 18 *M. tuberculosis* reference genomes retrieved from Genbank (accessions; [NC_000962.3](ncbi-n:NC_000962.3){#ir0015}, [NC_002755.2](ncbi-n:NC_002755.2){#ir0020}, [NC_009565.1](ncbi-n:NC_009565.1){#ir0025}, [NC_012943.1](ncbi-n:NC_012943.1){#ir0030}, [NC_016768.1](ncbi-n:NC_016768.1){#ir0035}, [NC_016934.1](ncbi-n:NC_016934.1){#ir0040}, [NC_017522.1](ncbi-n:NC_017522.1){#ir0045}, [NC_017523.1](ncbi-n:NC_017523.1){#ir0050}, [NC_017524.1](ncbi-n:NC_017524.1){#ir0055}, [NC_018078.1](ncbi-n:NC_018078.1){#ir0060}, [NC_020089.1](ncbi-n:NC_020089.1){#ir0065}, [NC_020559.1](ncbi-n:NC_020559.1){#ir0070}, [NC_021054.1](ncbi-n:NC_021054.1){#ir0075}, [NC_021192.1](ncbi-n:NC_021192.1){#ir0080}, [NC_021193.1](ncbi-n:NC_021193.1){#ir0085}, [NC_021194.1](ncbi-n:NC_021194.1){#ir0090}, [NC_021740.1](ncbi-n:NC_021740.1){#ir0095}, [NC_022350.1](ncbi-n:NC_022350.1){#ir0100}). A BLASTn all-against-all analysis was used to cluster CDS (percentage identity ≥ 90% and coverage ≥ 85%). Single representatives of each cluster were collated to form a non-redundant CDS list (preferentially selecting H37Rv reference CDS when present within a cluster). Non-H37Rv cluster representatives were screened against the H37Rv reference genome and removed if there was a BLASTn match with ≥ 90% identity and ≥ 85% coverage. (The H37Rv genome annotation has been well curated and thus we assume any sequence showing homology to regions of this genome, but which has not been annotated as a CDS in this genome, represents an erroneous annotation.) The presence of sequence regions representing each of the filtered, non-redundant CDS clusters (n = 3957) was estimated by BLASTn search against the *de novo* genome assemblies (percentage identity ≥ 90%, coverage ≥ 85%). Genes were considered putatively absent in cases where there was no BLAST match above the identity and coverage thresholds.

2.11. Association Tests {#s0065}
-----------------------

Genomic variants were tested for association with log MIC to amoxicillin/clavulanate. The association analysis used the amoxicillin/clavulanate MIC values directly rather than the dichotomous phenotype of resistant *vs.* susceptible. All SNVs for which base calls were available in all isolates were included in the analysis (including those in repeat regions, mobile elements, phage and PE/PPE genes). All genes represented by CDS in the filtered non-redundant list (see above) were also included in the analysis.

The initial sample consisted of 8580 SNVs and 8936 gene-content patterns. After excluding low frequency variants in which less than three isolates varied from all other isolates, 2555 SNVs and 228 gene-content patterns remained in the analysis. The close relatedness between many of the isolates in our sample leads to strong statistical dependencies between many pairs of variants, whose alleles have the same patterns across the sample. Such variants by definition comprise the same statistical hypothesis and result in the same *p*-value. We thus performed analysis of unique variant patterns, rather than of individual variants, and attached the *p*-value of each unique pattern to all SNVs having this pattern. Overall, 239 SNV patterns and 122 gene-content patterns (with an overlap of four patterns) were tested for association with drug resistance. FDR analysis was performed by considering the total number of tested hypotheses under both analyses.

A major challenge of genome-wide association testing is the presence of a population structure ([@bb0030]) in which sampled isolates are not identically and independently distributed. This can lead to spurious results due to confounding, *e.g.* in this case alleles that are common to a group of closely related susceptible isolates may falsely appear to be associated with ß-lactam susceptibility. To account for population structure in the setting of a quantitative phenotype (*e.g.* log-MIC), we applied a *phylogenetically aware* LMM ([@bb0155]). Given that *M. tuberculosis* is known to have a low rate of horizontal gene transfer ([@bb0200]), the effect of the population structure is assumed to be well-approximated by phylogeny. *p*-values were computed *via* simulation testing with one million simulations. See Supplemental Methods for more details.

3. Results {#s0070}
==========

3.1. Clinical Isolates of *M. tuberculosis* Exhibit a Broad Range of MICs to β-lactams {#s0075}
--------------------------------------------------------------------------------------

We screened a set of 91 *M. tuberculosis* strains of varying drug susceptibility patterns by determining the MIC to β-lactam/β-lactamase inhibitor combinations ([Table S1](#ec0010){ref-type="supplementary-material"}). Included clinical isolates of *M. tuberculosis* had been collected from 2008 to 2012 in KwaZulu-Natal, South Africa ([@bb0045]). Phenotypic assessment of a strain\'s susceptibility to amoxicillin, amoxicillin/clavulanate, meropenem and meropenem/clavulanate was performed by the drug Microplate Alamar Blue Assay (MABA), as previously described ([@bb0050], [@bb0210]).

Phenotypic testing of strains revealed universally high MICs to amoxicillin by itself ([Fig 1A](#f0005){ref-type="fig"}), which confirms innate mycobacterial resistance to this antibiotic alone among these strains. However, with the addition of clavulanate the mean MIC to amoxicillin lowered from 55.4 to 15.2 (Table S2), as numerous isolates were observed to have very low MICs to amoxicillin/clavulanate (Fig. 1B). With drug combination amoxicillin/clavulanate, 41/91 (45%) isolates had an MIC ≤ 4 μg/mL/2.5 μg/mL and as such were classified as susceptible to this regimen ([Table 1](#t0005){ref-type="table"}; [Table S1](#ec0010){ref-type="supplementary-material"}). Given the wide range of MICs observed for amoxicillin/clavulanate, a significant number of *M. tuberculosis* isolates may be amenable to treatment with this orally active β-lactam/β-lactamase inhibitor combination.

MIC determination was also performed for meropenem and meropenem/clavulanate. With meropenem alone, there was also a range of MICs observed among the tested isolates (Fig. 1C). With addition of clavulanate to meropenem (Fig. 1D), the mean observed MIC was lowered from 22.0 μg/mL for meropenem alone to 5.4 μg/mL/2.5 μg/mL for meropenem/clavulanate (Table S2). The resulting MIC\'s to meropenem and meropenem/clavulanate were consistent with those derived in a previous study ([@bb0135]).

3.2. Paradoxical Hypersusceptibility to β-lactams among MDR and XDR Isolates {#s0080}
----------------------------------------------------------------------------

Interestingly, strains that had previously been classified as MDR or XDR on first and second-line TB drug susceptibility testing were more frequently associated with amoxicillin/clavulanate susceptibility than isolates that were fully susceptible to first and second-line drugs ([Table 1](#t0005){ref-type="table"}). 14/24 (58%) MDR and 22/38 (58%) XDR isolates were classified as susceptible to amoxicillin/clavulanate, whereas only 3/21 (14%) first-line drug susceptible isolates were classified as susceptible to the same drug combination. Given that the overwhelming majority (18/21, 86%) of first-line susceptible strains including the reference laboratory strains H37Rv and CDC1551 were resistant to amoxicillin/clavulanate, it appeared paradoxical that MDR and XDR isolates would be susceptible to this drug combination. This was therefore termed "hypersusceptibility," to indicate gain of susceptibility.

3.3. *In vitro* Assessment of β-lactamase Activity {#s0085}
--------------------------------------------------

To determine whether observed differences in the MIC to amoxicillin/clavulanate were due to differential β-lactamase activity, a phenotypic assessment was performed by the nitrocefin hydrolysis assay (see Section [2](#s0010){ref-type="sec"}). A subset of 10 isolates with varying drug susceptibility patterns and a range of MICs to amoxicillin/clavulanate were selected for assessment (Table S3). All assayed strains, irrespective of drug susceptibility pattern or MIC to amoxicillin/clavulanate were able to hydrolyze nitrocefin, indicative of positive β-lactamase activity. This suggested that lack of β-lactamase activity did not account for low MICs to amoxicillin/clavulanate. These results are consistent with our observation that clavulanate addition is necessary to achieve a low MIC to amoxicillin.

3.4. Population Structure Reveals a Monophyletic Clade of LAM4 MDR and XDR Strains {#s0090}
----------------------------------------------------------------------------------

We conducted a comparative genomic analysis to understand the evolution of hypersusceptibility to amoxicillin/clavulanate in our panel of clinical isolates. All 91 β-lactam phenotyped strains had whole-genome sequences available for analysis ([@bb0045]). A Bayesian phylogeny ([Fig. 2](#f0010){ref-type="fig"}) was inferred from 7005 polymorphic sites identified through read-mapping and variant calling (Methods). In parallel, we performed an *in silico* spoligotype prediction (Methods) to contextualize the resulting population structure with respect to previously defined global *M. tuberculosis* lineages ([@bb0100], [@bb0125]) and SITVIT clades ([@bb0065], [@bb0280]). Strains represented 15 distinct shared types distributed across 11 SITVIT clades, each nesting within one of four global *M. tuberculosis* lineages ([Table 2](#t0010){ref-type="table"}; [Table S1](#ec0010){ref-type="supplementary-material"}).

There was an asymmetric distribution of MDR and XDR observed across the phylogeny ([Fig. 2](#f0010){ref-type="fig"}), as a disproportionate number of MDR and XDR isolates pertained to Lineage 4. More specifically, *in silico* spoligotyping revealed that these strains pertained to the LAM4 SITVIT clade and accounted for a great majority of MDR and XDR among the study isolates, with 68% and 85%, respectively. Of note, the LAM4 XDR strains clustered phylogenetically with reference strain KZN605 ([@bb0165], [@bb0145]), which was isolated in Tugela Ferry, KZN, South Africa in 2005 during the famed nosocomial XDR outbreak ([@bb0105]). A prior sequencing study by [@bb0045] has demonstrated that these same isolates are members of the clonal Tugela Ferry XDR epidemic in the region.

3.5. β-lactam Hypersusceptibility is Concentrated Within the Monophyletic Cluster of LAM4 {#s0095}
-----------------------------------------------------------------------------------------

While at least one strain susceptible to amoxicillin/clavulanate was observed in each of Lineages 1, 2 and 4, the vast majority (37/41 \[90.2%\]) of susceptible strains fell within Lineage 4 ([Fig. 2](#f0010){ref-type="fig"} and [Table 2](#t0010){ref-type="table"}). In fact, 32/41 (78%) of amoxicillin/clavulanate susceptible isolates pertained to the LAM4 clade, suggesting a monophyletic origin of hypersusceptibility.

In general, it can be difficult to disambiguate which genetic variants are responsible for a specific trait within a monophyletic clade as all genetic elements shared among the clade members will appear to be associated with that trait. However, the substantial phenotypic variability with respect to amoxicillin/clavulanate MIC despite limited genotypic variability in the LAM4 clade was suggestive that it may still be possible to identify key genomic variants responsible for or markers of the phenotype.

3.6. Comparative Genomic Analysis: Application of a Phylogenetically-aware Linear Mixed Model to Identify Candidate Variants {#s0100}
----------------------------------------------------------------------------------------------------------------------------

We next sought to test genomic markers of amoxicillin/clavulanate susceptibility using a phylogenetically-aware linear mixed model (LMM) ([@bb0155]) to identify candidate genomic variants. As our sample was dominated by a monophyletic phenotype of hypersusceptibility ([Fig. 2](#f0010){ref-type="fig"}), a phylogenetically-aware LMM was selected as this approach takes the phylogenetic structure into account and allows ranking of genomic phenotype-differentiating variants while remaining resilient to spurious variants ([@bb0030]). Single nucleotide polymorphisms (SNPs) and single nucleotide indels were considered together as single nucleotide variants (SNVs), and the goal of the analysis was focused on identifying genetic elements that differentiate closely related isolates that exhibit large phenotypic differences.

Rather than testing each independent SNV, variants were tested in groups defined by their pattern of representation across the set of genomes (*i.e.* variants shared by the same subset of genomes were grouped together). After excluding variants present in two or fewer genomes, we identified 239 distinct SNV groups. Due to the large number of tested hypotheses relative to the sample size, we controlled for the false discovery rate (FDR) rather than the family-wise error rate, using the Benjamini--Hochberg procedure ([@bb0010]). All *p*-values smaller than 1.68 × 10^− 3^ were determined to be significant at a 5% FDR, yielding 12 significant SNV groups. Of note, separately from the association analysis of SNVs, the LMM was also applied to a gene-content analysis (See Supplemental Results).

3.7. Identification of Twelve Significant Groups of Variants by LMM Analysis {#s0105}
----------------------------------------------------------------------------

The LMM analysis identified 12 significant groups of variants as highly associated with amoxicillin/clavulanate susceptibility, one of which included only a single synonymous variant ([Table 3](#t0015){ref-type="table"}, [Tables S4](#ec0015){ref-type="supplementary-material"} and S5). These twelve groups with significant *p*-values comprised a total of 38 individual SNVs which included: 17 non-synonymous mutations within predicted coding sequences, 16 synonymous mutations (Table S5); four intergenic polymorphisms, and a single nucleotide deletion within a predicted pseudogene (PE_PGRS36). Coding sequences included those associated with the following functions as defined in the TubercuList database ([@bb0180]) or as otherwise cited: first and second-line drug resistance (*rpoB*, *gyrA*, *ubiA* ([@bb0265])), virulence, transmembrane proteins (*ctpB*, *drrA*, Rv3921c) and cell wall synthesis (*aftD*, PE-PGRS genes ([@bb0020]) *pks12* ([@bb0220]) and *ubiA*). As mapping and variant calling within the PE/PPE genes is notoriously difficult due to extent of sequence repeats within these genes, our findings regarding SNVs in these genes should be considered cautiously. Intergenic SNVs included one upstream of *mmpL13a*, a transmembrane transport protein, and one within two nucleotides of the *espA* transcriptional start site ([@bb0240]).

3.8. Clustering of Variants Within *pks12* Likely Due to Recombination {#s0110}
----------------------------------------------------------------------

Interestingly, eight of the identified variants were located within a 34 bp region of the 5′ *pks12*, which included two non-synonymous and six synonymous mutations. *pks12* encodes a polyketide synthetase required for dimycocerosyl phthiocerol production, a major cell wall lipid that has been implicated in innate resistance to macrolides in *M. avium* ([@bb0250]) and described in other *M. tuberculosis* drug-resistant strains ([@bb0080]). This pattern of spatially clustered polymorphisms, previously observed in KZN-R506 ([@bb0145]), is highly unexpected, as TB has a low mutation rate. The longest open reading frame in *M. tuberculosis*, *pks12* spans 12,456 nucleotides and is composed of two near identical sequences (Fig. S1). Eight of the SNVs were clustered at 5′ Beta-ketoacyl synthase (bks) domain, after which the surrounding DNA sequence is identical to the corresponding sequence at the 3′ bks domain. Taken together, these findings suggest a recombination event had occurred rather than multiple independent point mutations ([@bb0085]). *pks12* has been identified by prior association studies in *M. tuberculosis* ([@bb0080]); however, given the length of the gene, its association with amoxicillin/clavulanate susceptibility may well be spurious.

3.9. Amoxicillin/Clavulanate Susceptibility Within the LAM4 Phylogeny {#s0115}
---------------------------------------------------------------------

In order to track the co-evolution of amoxicillin/clavulanate hypersusceptibility and first and second-line drug-resistance within LAM4, we investigated the significant SNVs in relationship to the LAM4 phylogeny ([Fig. 3](#f0015){ref-type="fig"}). A key observation was that 21/38 (55%) of the variants identified in our analyses were grouped into only four aggregates (indicated as A to D in [Fig. 3](#f0015){ref-type="fig"}), and each associated with a distinct division in the LAM4 sub-clade ([Table 3](#t0015){ref-type="table"}). Division B coincided with *rpoB* L452, which confers rifampicin resistance and emergence of MDR level drug-resistance. This analysis suggests that within the LAM4 subclade, MDR level-resistance and amoxicillin/clavulanate susceptibility appear to have emerged in tandem.

All the SNVs associated with divisions A--D occurred solely within the LAM4 clade, thus further analysis in other populations will be required to determine whether these SNVs represent markers of amoxicillin/clavulanate susceptibility among the broader *M. tuberculosis* population.

4. Discussion {#s0120}
=============

The global increase in MDR and XDR TB has prompted investigators to search for alternative treatment options, including repurposing of existing antibiotic therapies ([@bb0315]). While *M. tuberculosis* has traditionally been considered resistant to the β-lactams, there is emerging evidence that meropenem/clavulanate can have anti-tubercular activity relevant to the treatment of XDR-TB ([@bb0140]). However, the extent to which meropenem/clavulanate or other β-lactam/β-lactamase inhibitor combinations are effective against the wider *M. tuberculosis* population is unclear.

We performed a phenotypic screen of 91 *M. tuberculosis* strains ([@bb0045]) in order to determine the range of susceptibility to amoxicillin, amoxicillin/clavulanate, meropenem and meropenem/clavulanate. As expected, nearly all tested strains (94%) were susceptible to meropenem/clavulanate. Surprisingly, 45% of strains were also susceptible to amoxicillin/clavulanate, including a large proportion of MDR and XDR strains (58% each). As meropenem/clavulanate is intravenous, costly, and has multiple potential side effects ([@bb0195]), we chose to focus our investigation and discussion on amoxicillin/clavulanate, which is an inexpensive, oral, and globally accessible drug combination with an excellent safety profile ([@bb0270]).

We sought to further investigate the phenomenon of amoxicillin/clavulanate susceptibility using comparative genomics. A phylogenetic analysis indicated that a large proportion of MDR and XDR isolates in our dataset were part of a LAM4 clade, which was responsible for the famed Tugela Ferry XDR outbreak in KwaZulu-Natal in 2005 ([@bb0105]), and still accounts for a considerable burden of XDR ([@bb0040], [@bb0230], [@bb0110]). Additionally, a large proportion of amoxicillin/clavulanate susceptible isolates were also members of this clade, raising the possibility that this drug combination may be of benefit for individuals harboring these strains.

The pharmacodynamics of co-amoxiclav in the treatment of *M. tuberculosis* have not be formally studied. However for most bacteria the time above MIC (T \> MIC) is considered the principal determinant of efficacy ([@bb0285]). The slow growth of *M. tuberculosis* means an extended T \> MIC is likely to be critical for this organism. Despite this multiple and high dosing of co-amoxiclav could achieve drug levels expected to be active against *M. tuberculosis* strains with an MIC of ≤ 4 μg/mL/2.5 μg/mL amoxicillin/clavulanic acid ([@bb0035]).

Next we identified putative genomic markers of amoxicillin/clavulanate susceptibility through application of a phylogenetically-aware linear mixed model (LMM), which is suitable for samples wherein there is a large phenotypic variability within a group of closely related isolates (Supplementary material). The LMM identified 12 candidate variant patterns, comprising 38 unique variants ([Table 3](#t0015){ref-type="table"}, Table S5). It should be remembered that despite the use of a phylogenetically-aware LMM, association analyses cannot separate the effects of genomic variants that show linkage disequilibrium (*i.e.* those that represent the same pattern), a factor which must be considered when interpreting our results. Consequently, we do not infer causality, but rather suggest that the variants identified here represent genomic markers of amoxicillin/clavulanate susceptibility, which warrant further investigation.

Although our analyses did identify a number of interesting variants, we did not identify any associations between amoxicillin/clavulanate susceptibility and variation in genes previously implicated for this phenotype *e.g.* mycobacterial [l]{.smallcaps},[d]{.smallcaps}-transpeptidases, carboxypeptidases, penicillin-binding proteins ([@bb0075], [@bb0060], [@bb0170], [@bb0090], [@bb0015], [@bb0055], [@bb0070], [@bb0095], [@bb0225]). Furthermore, we found no evidence that altered β-lactamase genetics *or* activity accounts for observed differences in amoxicillin/clavulanate susceptibility. All 91 strains had a wild type *blaC*, the gene that encodes for the primary β-lactamase of *M. tuberculosis*. All strains in which β-lactamase activity was assessed---including strains with low MICs to amoxicillin/clavulanate---demonstrated the ability to hydrolyze nitrocefin, a β-lactam. Despite these findings, it is still conceivable that differences in BlaC expression may account for the observed range of β-lactam susceptibility, a hypothesis that will need to be tested in future experiments.

For *M. tuberculosis*, first and secon*d*-line drug susceptibility conforms to a classic model of drug resistance: wild type *M. tuberculosis* is susceptible to first and second-line antitubercular drugs (*e.g.* isoniazid, rifampin, ofloxacin, kanamycin *etc.*), and exposure to these same agents selects for resistant organisms. In contrast, our documentation of *M. tuberculosis* susceptibility to amoxicillin/clavulanate does not fit this classical model. Drug susceptible reference strains of *M. tuberculosis* and clinical isolates in basal phylogenetic groups ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}) had innate resistance to amoxicillin/clavulanate, yet clinical isolates were observed to be susceptible, suggesting that they had acquired susceptibility to these agents. To distinguish this phenomenon from the classic model of drug resistance, we have named this concept "paradoxical hypersusceptibility," which we define as phenotypic drug susceptibility observed in an organism in which its wild type state has innate resistance to that respective drug.

Further study will be necessary to fully elucidate the epidemiology of *in vitro* and *in vivo* susceptibility to β-lactam/β-lactamase inhibitor combinations globally and in other lineages of *M. tuberculosis*. The association between MDR and XDR clinical isolates and *in vitro* susceptibility to amoxicillin/clavulanate may provide effective treatment options for patients with XDR-TB, at least in regions of high LAM4 prevalence such as South Africa. However a recent study from Japan ([@bb0130]) suggests that drug-resistant strains with other genetic backgrounds also exhibit a similar phenotype. While the South African National TB program includes amoxicillin/clavulanate as part of a suggested drug regimen for XDR ([@bb0215]), only 61% of patients in a recently published long-term cohort of XDR in South Africa were prescribed this drug combination for at least some part of their treatment course ([@bb0255]). Given the poor treatment outcomes for XDR that have been reported, the fact that β-lactam drug susceptibility testing is not routinely performed, and relative safety of the drug, empiric addition of amoxicillin/clavulanate to patients with XDR-TB in South Africa may be advisable, although the optimal dosing regimen still needs to be established.

The following are the supplementary data related to this article.Supplemental Methods and Results.Image 1Table S1Study isolates are listed with sequencing identifiers, first/second-line DST pattern, MICs to amoxicillin, amoxicillin/clavulanate, meropenem and meropenem/clavulanate in addition to resistance or susceptibility classification to the respective antibiotics. "ND" indicates that phenotyping to that antibiotic was not performed for that isolate. Global *M. tuberculosis* lineage, SITVIT designation and spoligotype for each isolate were inferred *in silico*.Table S1:Table S4Association testing results.Table S4:Table S6List of candidate genes identified *via* a literature search that may be hypothesized to be associated with β-lactam susceptibility.Table S6:
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![Clinical isolates of *M. tuberculosis* exhibit a range of susceptibility to β-lactam/β-lactamase inhibitors. 91 isolates of *M. tuberculosis* underwent MIC determination to A) amoxicillin, B) amoxicillin/clavulanate, C) meropenem, and D) meropenem/clavulanate. MICs are reported by β-lactam concentration, and clavulanate concentration was held constant at 2.5 μg/mL.](gr1){#f0005}

![Amoxicillin/clavulanate hypersusceptible isolates were largely clustered within a monophyletic XDR group within the LAM4 clade. A Bayesian phylogeny of 91 *M. tuberculosis* isolates, rooted with the *M. canettii* outgroup, is shown. Bootstrap support values \> 80% are marked by an asterisk. Globally recognised *M. tuberculosis* lineages are indicated. Amoxicillin/clavulanate MICs are represented in a horizontal bar graph to the right of the tree. MICs are reported by amoxicillin concentration, and clavulanate concentration was held constant at 2.5 μg/mL. As indicated in the figure key, the MIC bar graph is color-coded according to the first and second-line drug susceptibility patterns of the corresponding strain. The shaded box indicates LAM4 strains; a monophyletic cluster of spoligotype LAM4 strains with MDR and XDR level resistance is observed within lineage 4. While a significant number of isolates with hypersusceptibility to amoxicillin/clavulanate were concentrated within the LAM4 XDR clade, there are other notable examples of hypersusceptible strains that pertain to other global lineages and spoligotypes.](gr2){#f0010}

![Tracing the emergence of amoxicillin/clavulanate susceptibility within the LAM4 clade. A. Bayesian phylogeny of 91 *M. tuberculosis* isolates as represented in [Fig. 2](#f0010){ref-type="fig"}. The LAM4 clade is marked by the blue box and is magnified in B. Nodes with bootstrap support values \> 80% are marked by an asterisk. Nodes A-D define subclade divisions for which the corresponding pattern of genomic variants listed in [Table 3](#t0015){ref-type="table"} is conserved among all members of the subclade. Amoxicillin/clavulanate MICs (amoxicillin μg/mL, clavulanate concentration fixed at 2.5 μg/mL) are represented in a horizontal bar graph to the right of the tree. The bar graph is color-coded according to first and second-line drug susceptibility patterns as in [Fig. 2](#f0010){ref-type="fig"}. Historic LAM4 strains are identified by name: KZN605 (XDR), KZN1435 (MDR) and KZN4207 (first/second-line drug susceptible).](gr3){#f0015}

###### 

A disproportionate number of MDR and XDR strains were susceptible to amoxicillin/clavulanate. Susceptibility to amoxicillin or amoxicillin/clavulanate was defined as MIC ≤ 4 μg/mL of the amoxicillin component. Susceptibility to meropenem or meropenem/clavulanate was defined as MIC ≤ 12 μg/mL of the meropenem component. Clavulanate was 2.5 μg/mL.

Table 1

  First and second-line DST category   Amoxicillin susceptibility   Amoxicillin/Clavulanate susceptibility   Meropenem susceptibility   Meropenem/Clavulanate susceptibility
  ------------------------------------ ---------------------------- ---------------------------------------- -------------------------- --------------------------------------
  Susceptible                          0/21 (0%)                    3/21 (14%)                               3/16 (19%)                 14/16 (87.5%)
  Mono-drug resistant                  0/3 (0%)                     0/3 (0%)                                 0/3 (0%)                   3/3 (100%)
  Poly-drug resistant                  0/5 (0%)                     2/5 (40%)                                1/5 (20%)                  5/5 (100%)
  MDR                                  0/24 (0%)                    14/24 (58%)                              5/18 (28%)                 19/21 (90%)
  XDR                                  1/38 (3%)                    22/38 (58%)                              11/36 (31%)                36/37 (97%)
  Total                                1/91 (1%)                    41/91 (45%)                              20/78 (26%)                77/82 (94%)

###### 

Frequency and distribution of DST patterns and amoxicillin/clavulanate susceptibility determination across *M. tuberculosis* global lineages and SITVIT clades.

Table 2

  *M. tuberculosis* lineage   Spoligotype designation   Total number of strains per spoligotype   First/second-line DST patterns   Amoxicillin/clavulanate susceptibilities                                    
  --------------------------- ------------------------- ----------------------------------------- -------------------------------- ------------------------------------------ ---------- ---------- ---------- ----------
  1                           EAI1-SOM                  2                                         --                               1 (50%)                                    1 (50%)    --         2 (100%)   --
  2                           Beijing                   20                                        6 (30%)                          5 (25%)                                    5 (25%)    4 (20%)    2 (10%)    18 (90%)
  3                           CAS1-Kili                 1                                         --                               1 (100%)                                   --         --         --         1 (100%)
  4                           H1                        1                                         1 (100%)                         --                                         --         --         1 (100%)   --
                              H37Rv                     2                                         2 (100%)                         --                                         --         --         --         2 (100%)
                              LAM3                      4                                         3 (75%)                          --                                         --         1 (25%)    --         4 (100%)
                              LAM4                      47                                        4 (9%)                           1 (2%)                                     13 (28%)   29 (62%)   32 (68%)   15 (32%)
                              S                         4                                         --                               --                                         4 (100%)   --         1 (25%)    3 (75%)
                              T1                        3                                         2 (67%)                          --                                         1 (33%)    --         1 (33%)    2 (67%)
                              T3                        1                                         --                               --                                         --         1 (100%)   --         1 (100%)
                              X3                        5                                         2 (40%)                          --                                         --         3 (60%)    1 (20%)    4 (80%)
                              UND                       1                                         1 (100%)                         --                                         --         --         1 (100%)   --
  Total                                                 91                                        21 (23%)                         8 (9%)                                     24 (26%)   37 (41%)   41 (45%)   50 (55%)

Lineages and SITVIT clades inferred from *in silico* spoligotype data (see Section [2](#s0010){ref-type="sec"}). UND = undesignated spoligotype. First/second-line drug susceptibility (DST) results are abbreviated as follows: susceptible, mono or poly-drug resistant (Mono/Poly), multi-drug resistant (MDR) and extensively drug resistant (XDR). For amoxicillin/clavulanate susceptibility, strains were designated susceptible and resistant based on an MIC ≤ 4 μg/mL of the amoxicillin component.

###### 

Single nucleotide variants (non-synonymous and intergenic) identified as putative genomic markers of amoxicillin/clavulanate susceptibility.

Table 3

  Genomic loci   Rv number         Gene name                Effect\*    Amino acid effect   \# Isolates   *p*-Value    LAM4 sub-clade
  -------------- ----------------- ------------------------ ----------- ------------------- ------------- ------------ ----------------
  664929         Rv0571c-Rv0572c   --                       C ➜ A       Intergenic          28            1.28E − 04   D
  761161         Rv0667            *rpoB*                   cTg ➜ cCg   L452P               36            2.40E − 04   B
  1272321        Rv1144-Rv1145     −* mmpL13a*              C ➜ A       Intergenic          36            2.40E − 04   B
  2,300,674      Rv2048c           *pks12*                  Aac ➜ Gac   N2105D              36            2.40E − 04   B
  2300676        Rv2048c           *pks12*                  tAc ➜ tTc   Y2104F              36            2.40E − 04   B
  3889150        Rv3471c           --                       gaC ➜ gaA   D64E                36            2.40E − 04   B
  761110         Rv0667            *rpoB*                   gAc ➜ gGc   D435G               30            2.88E − 04   C
  763123         Rv0667            *rpoB*                   aTc ➜ aCc   I1106T              30            2.88E − 04   C
  2246032        Rv2000            --                       cTg ➜ cCg   L275P               30            2.88E − 04   C
  4056430        Rv3616c-Rv3617    *espA*-*ephA*            T ➜ C       Intergenic          30            2.88E − 04   C
  1212626        Rv1087            PE_PGRS21                gAc ➜ gCc   D356A               36            3.04E − 04   --
  7570           Rv0006            *gyrA*                   gCg ➜ gTg   A90 V               32            4.96E − 04   --
  4269271        Rv3806c           *ubiA*                   gTg ➜ gCg   V188 A              31            6.08E − 04   --
  1532777        Rv1361c           PPE19                    cAg ➜ cGg   Q286R               45            1.10E − 03   --
  122107         Rv0103c           *ctpB*                   Ggt ➜ Agt   G23S                42            1.17E − 03   A
  3272997        Rv2936            *drrA*                   Agg ➜ Ggg   R262G               42            1.17E − 03   A
  283614         Rv0236c           *aftD*                   Agc ➜ Ggc   S1080G              8             1.25E − 03   --
  340372         Rv0280            PPE3                     Tcg ➜ Ccg   S337P               8             1.25E − 03   --
  2357269        Rv2098c           PE_PGRS36 (pseudogene)   G➜          Deletion            8             1.25E − 03   --
  3462135        Rv3093c           --                       tgC ➜ tgG   C210W               8             1.25E − 03   --
  3942640        Rv3512            PE_PGRS56                aTt ➜ aCt   I306T               8             1.25E − 03   --
  2074509        Rv1829-Rv1830     --                       C ➜ G       Intergenic          45            1.40E − 03   --

Genomic loci as defined in the H37Rv reference genome. For single nucleotide polymorphisms 'Effect' indicates the base differences (base in reference ➜ alternative base), polymorphisms within coding sequence regions are shown as capital letters in the context of the codons to which they belong (other positions shown in lower case). \# Isolates indicates the number of *M. tuberculosis* strains that contained the corresponding polymorphism. LAM4 sub-clade indicates the sub-clade for which the SNP in question is both unique to and conserved across the sub-clade. All SNVs having the same *p*-value represent the same evolutionary pattern. Of note, our analyses did not identify any associations between amoxicillin/clavulanate susceptibility and variation in genes previously implicated for this phenotype *e.g.* mycobacterial [l]{.smallcaps},[d]{.smallcaps}-transpeptidases, carboxypeptidases, penicillin-binding proteins and the BlaC beta-lactamase among others ([@bb0075], [@bb0060], [@bb0170], [@bb0090], [@bb0015], [@bb0055], [@bb0070], [@bb0095], [@bb0225]) ([Table S6](#ec0020){ref-type="supplementary-material"}).

Genomic loci as defined in the H37Rv reference genome. For single nucleotide polymorphisms 'Effect' indicates the base differences (base in reference ➜ alternative base), polymorphisms within coding sequence regions are shown as capital letters in the context of the codons to which they belong (other positions shown in lower case). \# Isolates indicates the number of *M. tuberculosis* strains that contained the corresponding polymorphism. LAM4 sub-clade indicates the sub-clade for which the SNP in question is both unique to and conserved across the sub-clade. All SNVs having the same *p*-value represent the same evolutionary pattern. Of note, our analyses did not identify any associations between amoxicillin/clavulanate susceptibility and variation in genes previously implicated for this phenotype *e.g.* mycobacterial [l]{.smallcaps},[d]{.smallcaps}-transpeptidases, carboxypeptidases, penicillin-binding proteins and the BlaC beta-lactamase among others ([@bb0075], [@bb0060], [@bb0170], [@bb0090], [@bb0015], [@bb0055], [@bb0070], [@bb0095], [@bb0225]) (Table S6).
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